Last mentioned: 17h ago
Across the most recent 6 stories covering Bristol Myers Squibb — 100% neutral sentiment, averaging 6.5/10 impact.
This entity profile aggregates every story where the entity meets our minimum relevance threshold before it is linked here — a story naming this entity only in passing, as competitive context for an unrelated subject, does not qualify. That threshold exists because earlier testing surfaced entity pages cluttered with tangential mentions: a story about two unrelated companies merging could otherwise populate a third company's page simply because it was named once for comparison, with no real event of its own. The timeline below reflects genuine milestones and developments specific to this entity, cross-referenced against the same source-verification standard applied to every story on this site. Sentiment measures the directional read of each development for this entity specifically, not the overall tone of the reporting, and impact weights how consequential a development is rather than how widely it was syndicated across outlets.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
DCAT Week 2026
LOTTE Biologics engages in high-level partnership talks in New York City.
ADC Expansion
Completion of specialized ADC manufacturing lines at the Syracuse facility.
Songdo Groundbreaking
Construction begins on the first Mega Plant in Songdo, South Korea.
Syracuse Acquisition
LOTTE Biologics completes the acquisition of the Syracuse, NY plant from Bristol Myers Squibb.
The potential combination of two pharmaceutical powerhouses would concentrate ownership of critical cardiovascular and oncology treatments, raising concerns about pricing power, NHS supply chains, and worldwide health equity.
A potential $400 billion merger between AstraZeneca and Bristol Myers Squibb could reshape oncology competition, with implications for drug costs, patient access, and payer negotiations. The combined portfolio would dominate key cancer markets.
Pfizer and Bristol Myers Squibb combine high dividend yields with deep healthcare pipelines, offering a compelling income-entry into a sector facing patent cliffs but also rich in innovation. For healthcare investors, the stocks demand a long-term view on drug development amid evolving policy risks.
Source: The Motley Fool · fool.com
Both Nyxoah and Alumis reported quarterly earnings that missed analyst expectations by $0.04 per share, reflecting the high operational costs of late-stage clinical trials and pre-commercialization activities. Despite the financial shortfall, both companies remain on track with pivotal regulatory and clinical milestones in the sleep apnea and immunology sectors.
Source: tickerreport.com · dailypolitical.com
New research indicates that patients with Mild Cognitive Impairment (MCI) and dementia are at a significantly higher risk for developing cardiovascular conditions requiring anticoagulants. This finding underscores the clinical challenge of managing stroke prevention in cognitively impaired populations with high fall risks.
Source: psychiatryadvisor.com · neurologyadvisor.com
LOTTE Biologics is attending DCAT Week 2026 in New York to secure high-value global partnerships and solidify its position in the CDMO market. This move underscores the company's aggressive strategy to leverage its U.S. manufacturing footprint and upcoming South Korean capacity.
Source: singaporestar.com · cambodiantimes.com
This page surfaces every story mentioning Bristol Myers Squibb across our healthcare coverage. We track each entity's appearance over time so readers can trace how the narrative evolves — which developments are isolated incidents, which build into longer arcs, and which reframe how operators in the space think about the entity. Story selection uses the same multi-source verification gate applied across the rest of our coverage.
Read our editorial methodology for how we identify, deduplicate, and score entity references. Our glossary defines the technical terms used across stories on this page, and our trends index contextualizes individual developments against the longer-running healthcare beat. Cross-entity comparisons live on our compare view.
Entities only appear on this page once the classifier scores them at a minimum 35 percent relevance to the story, filtering out passing mentions. According to that methodology, reviewed July 2026, this follows multi-source corroboration standards recommended by journalism research bodies such as the Reuters Institute for the Study of Journalism.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
| What you see | What it tells you |
|---|---|
| Story count | Number of distinct stories where Bristol Myers Squibb was a primary or referenced actor. |
| Recency clustering | Whether mentions are concentrated in a recent window (a news cycle) or distributed (a sustained arc). |
| Sentiment distribution | Aggregate sentiment of the stories mentioning this entity, weighted by impact score. |
| Cross-niche links | When the same entity surfaces in our sibling networks, we link to those views to enrich context. |